Stock Scorecard



Stock Summary for Theravance Biopharma Inc (TBPH) - $16.31 as of 4/2/2026 6:42:05 PM EST

Total Score

14 out of 30

Safety Score

31 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for TBPH

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for TBPH

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for TBPH

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for TBPH

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for TBPH (31 out of 100)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 9
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 6
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for TBPH

TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm 4/3/2026 12:39:00 AM
How Theravance Biopharma Inc. (TBPH) Affects Rotational Strategy Timing 4/1/2026 7:56:00 PM
Theravance (NASDAQ: TBPH) sets 2039 generic date in YUPELRI patent settlement 3/31/2026 4:10:00 AM
Theravance Biopharma Inc. (TBPH) has disclosed that a settlement agreement has been filed with the U.S. Securities and Exchange Commission (SEC), and is currently under review by the Department of Justice and the Federal Trade Commission. 3/31/2026 12:10:00 AM
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement 3/30/2026 11:10:00 PM
Theravance Biopharma Inc. (TBPH) has disclosed that a settlement agreement has been filed with the U.S. Securities and Exchange Commission (SEC), and is currently under review by the Department of Justice and the Federal Trade Commission. 3/30/2026 5:10:00 PM
Theravance Biopharma (NASDAQ:TBPH) Raised to "Strong-Buy" at Wall Street Zen 3/29/2026 5:39:00 AM
Theravance Biopharma (TBPH) price target decreased by 39.48% to 16.49 3/28/2026 3:10:00 AM
Theravance Biopharma (TBPH) price target decreased by 39.48% to 16.49 3/27/2026 11:08:00 PM
TBPH Guided for $75M in Milestones While Trial Risk Went Unquantified -- LEVI & KORSINSKY, LLP 3/26/2026 1:10:00 PM

Financial Details for TBPH

Company Overview

Ticker TBPH
Company Name Theravance Biopharma Inc
Country N/A
Description Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 12/31/2025
Next Earnings Date 5/14/2026

Stock Price History

Last Day Price 16.31
Price 4 Years Ago 11.22
Last Day Price Updated 4/2/2026 6:42:05 PM EST
Last Day Volume 677,047
Average Daily Volume 853,863
52-Week High 21.03
52-Week Low 7.90
Last Price to 52 Week Low 106.46%

Valuation Measures

Trailing PE N/A
Industry PE 28.01
Sector PE 53.11
5-Year Average PE -37.76
Free Cash Flow Ratio 4.96
Industry Free Cash Flow Ratio 13.11
Sector Free Cash Flow Ratio 28.27
Current Ratio Most Recent Quarter 10.93
Total Cash Per Share 3.29
Book Value Per Share Most Recent Quarter 5.81
Price to Book Ratio 2.56
Industry Price to Book Ratio 10.39
Sector Price to Book Ratio 21.37
Price to Sales Ratio Twelve Trailing Months 7.27
Industry Price to Sales Ratio Twelve Trailing Months 22.78
Sector Price to Sales Ratio Twelve Trailing Months 25.63
Analyst Buy Ratings 5
Analyst Strong Buy Ratings 0

Share Statistics

Total Shares Outstanding 51,069,000
Market Capitalization 832,935,390
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 287.70%
Reported EPS 12 Trailing Months 2.06
Reported EPS Past Year 0.00
Reported EPS Prior Year -0.13
Net Income Twelve Trailing Months 105,895,000
Net Income Past Year 105,895,000
Net Income Prior Year -56,418,000
Quarterly Revenue Growth YOY 144.70%
5-Year Revenue Growth 8.38%
Operating Margin Twelve Trailing Months 43.60%

Balance Sheet

Total Cash Most Recent Quarter 167,806,000
Total Cash Past Year 167,806,000
Total Cash Prior Year 37,797,000
Net Cash Position Most Recent Quarter 167,806,000
Net Cash Position Past Year 167,806,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 616,334,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 296,723,000
Total Stockholder Equity Prior Year 175,545,000
Total Stockholder Equity Most Recent Quarter 296,723,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 238,499,000
Free Cash Flow Per Share Twelve Trailing Months 4.67
Free Cash Flow Past Year 238,499,000
Free Cash Flow Prior Year -11,867,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 13.86
20-Day Bollinger Middle Band 18.08
20-Day Bollinger Upper Band 22.30
Beta 0.11
RSI 0.00
50-Day SMA 0.00
150-Day SMA 11.04
200-Day SMA 10.82

System

Modified 4/2/2026 9:31:26 AM EST